 "Sun Pharma, Ranbaxy hit fresh high on Punjab & Haryana High Court nod for merger")
Shares of Sun Pharmaceutical Industries and Ranbaxy Laboratories have touched their respective all-time highs after Punjab and Haryana High Court approved the Scheme of Arrangement involving merger of Ranbaxy Laboratories with Sun Pharmaceutical Industries.
Sun Pharma and Ranbaxy Laboratories has informed BSE that the Hon’ble High Court of Punjab & Haryana has orally pronounced the Order on March 09, 2015, approving the Scheme of Arrangement involving merger of Ranbaxy Laboratories with Sun Pharmaceutical Industries under Sections 391 to 394, Sections 78 and 100 of the Companies Act. 1956 and Section 52 of the Companies Act, 2013.
Certified true copy of the Order is awaited, it added.
Shares of Ranbaxy Laboratories have moved higher by 2.4% at Rs 825, also its record high on BSE, post announcements. The stock has recovered nearly 5% from its intra-day low of Rs 787 touched in early morning trade.
Sun Pharma too up 1% at Rs 1,049, also its new high, bouncing back about 4% from intra-day low. The stock opened at Rs 1,024 and hit a low of Rs 1,009 on BSE.
Sun Pharma and Ranbaxy Laboratories has informed BSE that the Hon’ble High Court of Punjab & Haryana has orally pronounced the Order on March 09, 2015, approving the Scheme of Arrangement involving merger of Ranbaxy Laboratories with Sun Pharmaceutical Industries under Sections 391 to 394, Sections 78 and 100 of the Companies Act. 1956 and Section 52 of the Companies Act, 2013.
Certified true copy of the Order is awaited, it added.
Shares of Ranbaxy Laboratories have moved higher by 2.4% at Rs 825, also its record high on BSE, post announcements. The stock has recovered nearly 5% from its intra-day low of Rs 787 touched in early morning trade.
Sun Pharma too up 1% at Rs 1,049, also its new high, bouncing back about 4% from intra-day low. The stock opened at Rs 1,024 and hit a low of Rs 1,009 on BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%